Colorectal Cancer Diagnostics Market (By Test Type: Blood Test, Stool Test, Fecal Occult Blood Test, Fecal Biomarker Test, CRC DNA Screening Test, Imaging Test, Computed Tomography scan, Ultrasound, Magnetic Resonance Imaging scan, Positron Emission Tomography scan, Colonoscopy, Other Imaging Tests, Biopsy, Other Test Types; By End-use: Hospitals, Diagnostic Imaging Centers, Cancer Research Centers, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global colorectal cancer diagnostics market size was valued at USD 14.25 billion in 2023 and is anticipated to reach around USD 33.48 billion by 2033, growing at a CAGR of 8.92% from 2024 to 2033. The colorectal cancer diagnostics market is driven by the increasing focus on screening and early detection initiatives.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. colorectal cancer diagnostics market size was estimated at USD 4.56 billion in 2023 and is predicted to be worth around USD 10.92 billion by 2033 at a CAGR of 9.12% from 2024 to 2033.
North America had the largest market share in 2023 in the colorectal cancer diagnostics market. In North America, both the public and healthcare professionals are becoming more aware of colorectal cancer and the value of routine screening. Governments, healthcare organizations, and advocacy groups aggressively promote screening programs. This results in a rise in diagnostic procedures such as colonoscopies, fecal occult blood tests (FOBT), and fecal immunochemical tests (FIT). Research institutes, pharmaceutical companies, and diagnostic businesses frequently work together in this region on R&D projects to enhance colorectal cancer detection. These partnerships increase market penetration, promote innovation, and quicken the creation of new diagnostic instruments.
Asia-Pacific is observed to be the fastest growing colorectal cancer diagnostics market during the forecast period. The incidence of colorectal cancer in the region is rising, mainly due to aging populations, altered eating patterns and changing lifestyles. Several factors, including sedentary lifestyles, a high intake of processed foods, and little physical activity, are linked to the rising incidence of colorectal cancer in Asia-Pacific nations. Healthcare spending is rising in line with the continued growth of the economies in the Asia-Pacific region. Spending on preventive healthcare measures, such as routine colorectal cancer screenings, is increasing among individuals. The region's colorectal cancer diagnostics market is also growing due to government programs and insurance coverage for cancer screening and treatment.
The Asia Pacific colorectal cancer diagnostics market size was calculated at USD 3.42 billion in 2023 and is projected to expand around USD 8.20 billion by 2033, poised to grow at a CAGR of 9.13% from 2024 to 2033.
Year | Market Size (USD Billion) |
2023 | 3.42 |
2024 | 3.72 |
2025 | 4.06 |
2026 | 4.42 |
2027 | 4.81 |
2028 | 5.24 |
2029 | 5.71 |
2030 | 6.22 |
2031 | 6.77 |
2032 | 7.38 |
2033 | 8.20 |
The area of the healthcare business dedicated to creating, manufacturing, and distributing diagnostic instruments and tests to identify and track colorectal cancer is known as the colorectal cancer diagnostics market. One of the most common and dangerous types of cancer in the world is colorectal cancer, which also encompasses tumors of the colon and the rectum. Patient outcomes and survival rates are greatly enhanced by early identification of colorectal cancer. Colonoscopies, stool DNA testing, fecal occult blood tests (FOBT), imaging methods, and other diagnostic procedures are vital in detecting colorectal cancer in its early stages when therapy is most successful.
The colorectal cancer diagnostics market comprises a sizeable portion of the more significant oncology diagnostics industry. Market expansion is facilitated by ongoing technology developments, such as creating non-invasive and more accurate diagnostic techniques. Furthermore, the accuracy and dependability of colorectal cancer diagnostics are improved by introducing innovative biomarkers and molecular diagnostic methods.
Report Coverage | Details |
Growth Rate from 2024 to 2033 | CAGR of 8.92% |
Colorectal Cancer Diagnostics Market Size in 2023 | USD 14.25 Billion |
Colorectal Cancer Diagnostics Market Size in 2024 | USD 15.52 Billion |
Colorectal Cancer Diagnostics Market Size by 2033 | USD 33.48 Billion |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | By Test Type and By End-use |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Drivers
Rising prevalence of colorectal cancer
Spending more on healthcare, especially in industrialized nations, makes modern colorectal cancer diagnostics and therapies more accessible. Patients gain better access to screening programs and diagnostic centers as governments and healthcare institutions devote resources to cancer prevention, detection, and management. The growing expenditure on healthcare infrastructure is driving the growth of the market for colorectal cancer diagnostics. Thereby, the rising prevalence of colorectal cancer is observed to act as a driver for the colorectal cancer diagnostics market.
Growing preference for non-invasive diagnostic methods
The market for colorectal cancer diagnostics is driven by consumers' increasing demand for non-invasive diagnostic techniques, altering how this common cancer is identified and treated. One of the most common malignancies detected worldwide, colorectal cancer, has historically been linked to invasive diagnostic procedures, including sigmoidoscopies and colonoscopies. However, the development of non-invasive diagnostic methods has changed how medical practitioners approach this disease's detection and surveillance.
Restraints
Lack of awareness among the general population regarding the importance of colorectal cancer screening
Despite the availability of efficient screening techniques, including sigmoidoscopy, colonoscopy, and fecal occult blood tests (FOBT), many people do not regularly engage in screening programs because they are unaware of their significance. This hesitation could be brought on by false beliefs about the difficulty of screening tests, anxiety over being diagnosed with cancer, or ignorance of the possible advantages of early detection. Despite people's awareness of the significance of colorectal cancer screening, several obstacles may keep them from utilizing screening services.
These obstacles include the absence of health insurance, budgetary limitations, travel time to screening locations, and linguistic or cultural hurdles. Insufficient knowledge worsens these obstacles by making impacted populations feel that screening is not as important or urgent.
Limitations in the accuracy and reliability of certain tests
Sampling errors can occur in certain diagnostic tests, especially tissue or stool samples. The diagnostic process's reliability can be threatened by erroneous test results resulting from inadequate sampling or inappropriate sample handling. Due to various genetic alterations and molecular subtypes, colorectal cancer is heterogeneous. The biological variability among tumors might impact diagnostic tests' performance to target specific biomarkers or molecular signatures, resulting in inconsistent test results and diagnostic accuracy.
Opportunities
Growing opportunity for personalized medicine approaches
Personalized medicine empowers Patients to participate more actively in their healthcare journeys. A patient-centric style of care that puts efficacy, safety, and quality of life first is fostered by personalized medicine, which customizes diagnostic and therapeutic techniques to everyone's distinct biology and preferences. Individualized strategies help patients with colorectal cancer not only increase their chances of survival but also improve their general health and level of satisfaction with their medical care.
Innovations in imaging technologies
High-resolution images of the colon and rectum are provided by imaging technologies like CT, MRI, and PET scans, which enable medical practitioners to spot abnormal growths like polyps or cancers early on. To allow timely intervention and increase the chance of effective treatment, early identification is essential in the management of colorectal cancer. The potential for enhancing colorectal cancer diagnosis by integrating artificial intelligence (AI) and machine learning algorithms with imaging technology is enormous. AI-based image analysis can help radiologists analyze imaging data more effectively and precisely, resulting in quicker diagnosis and more targeted therapy suggestions.
The imaging test segment dominated in the colorectal cancer diagnostics market in 2023. Unmatched ability to identify anomalies in the colon and rectum is provided by imaging procedures, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). By detecting worrisome growths, polyps, or tumors in their early stages, these tests can significantly enhance patient outcomes by facilitating early management. A thorough evaluation of the degree and dissemination of colorectal cancer is possible with imaging testing.
They include comprehensive details regarding the size, location, invasion of surrounding tissues, and involvement of distant organs or neighboring lymph nodes. Accurately diagnosing the disease and choosing the best course of treatment depends on this thorough evaluation.
The blood test segment is observed to be the fastest growing in the colorectal cancer diagnostics market during the forecast period. Both people and medical professionals find blood tests to be a non-invasive way to diagnose colorectal cancer. Blood testing offers a relatively easy and practical alternative to more intrusive and uncomfortable traditional screening techniques like colonoscopies. Because it is non-invasive, more people are encouraged to get screened, raising market demand. One of the main reasons why blood tests are so popular with patients is their ease. Unlike colonoscopies, blood tests are usually quick and require little preparation, which may involve intestinal preparation and downtime.
More people follow screening recommendations due to this convenience, especially those who might not otherwise want to have intrusive procedures done. Consequently, blood test recommendations from healthcare professionals as part of standard screening procedures are more likely, which propels market expansion.
The hospitals segment dominated the colorectal cancer diagnostics market in 2023. A multidisciplinary team of oncologists, surgeons, radiologists, pathologists, and other experts is frequently involved in treating colorectal cancer. Hospitals give these specialists a place to work together, resulting in more precise diagnoses and individualized treatment regimens catered to each patient's requirements. Hospitals employ skilled medical personnel with a focus on the diagnosis and treatment of colorectal cancer. These experts have received substantial training and experience in interpreting diagnostic tests and identifying subtle indicators of colorectal cancer, which enables prompt intervention and better patient outcomes.
The diagnostic imaging centers segment is observed to be the fastest growing in the colorectal cancer diagnostics market during the forecast period. One of the most common diseases in the world, colorectal cancer is becoming more common, especially in affluent nations. There's a growing need for better diagnostic services to control the disease burden as the world's population ages, and lifestyle factors, including poor diet and sedentary behavior, contribute to the rising incidence of colorectal cancer. With their cutting-edge imaging equipment, diagnostic imaging facilities can provide prompt and precise diagnosis, which makes them essential in the fight against colorectal cancer.
Segments Covered in the Report
By Test Type
By End-use
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Colorectal Cancer Diagnostics Market
5.1. COVID-19 Landscape: Colorectal Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Colorectal Cancer Diagnostics Market, By Test Type
8.1. Colorectal Cancer Diagnostics Market, by Test Type, 2024-2033
8.1.1. Blood Test
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Stool Test
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Fecal Occult Blood Test (FOBT)
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Fecal Biomarker Test
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. CRC DNA Screening Test
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Imaging Test
8.1.6.1. Market Revenue and Forecast (2021-2033)
8.1.7. Computed Tomography (CT) scan
8.1.7.1. Market Revenue and Forecast (2021-2033)
8.1.8. Ultrasound
8.1.8.1. Market Revenue and Forecast (2021-2033)
8.1.9. Magnetic Resonance Imaging (PET) scan
8.1.9.1. Market Revenue and Forecast (2021-2033)
8.1.10. Positron Emission Tomography (PET) scan
8.1.10.1. Market Revenue and Forecast (2021-2033)
8.1.11. Colonoscopy
8.1.11.1. Market Revenue and Forecast (2021-2033)
8.1.12. Other Imaging Tests
8.1.12.1. Market Revenue and Forecast (2021-2033)
8.1.13. Biopsy
8.1.13.1. Market Revenue and Forecast (2021-2033)
8.1.14. Other Test Types
8.1.14.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Colorectal Cancer Diagnostics Market, By End-use
9.1. Colorectal Cancer Diagnostics Market, by End-use, 2024-2033
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Diagnostic Imaging Centers
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Cancer Research Centers
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Colorectal Cancer Diagnostics Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.1.2. Market Revenue and Forecast, by End-use (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.1.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.1.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.2.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.2.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.2.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.2.5.2. Market Revenue and Forecast, by End-use (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.2.6.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.3.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.3.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.3.5.2. Market Revenue and Forecast, by End-use (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.3.6.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.4.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.4.4.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.4.5.2. Market Revenue and Forecast, by End-use (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.4.6.2. Market Revenue and Forecast, by End-use (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.5.2. Market Revenue and Forecast, by End-use (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.5.3.2. Market Revenue and Forecast, by End-use (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
10.5.4.2. Market Revenue and Forecast, by End-use (2021-2033)
Chapter 11. Company Profiles
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. BioMerieux SA
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Dickinson and Company
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. GE Healthcare
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Qiagen N.V
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Thermo Fischer Scientific
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Hologic Inc
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Epigenomics AG
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. F-Hoffmann-La Roche Ltd
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Siemens Healthineers
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client